CalciMedica Q2 net loss $7.7M, $49M financing, FDA aligns on AP trial

CalciMedica, Inc.

Net loss Q2 2026 $7.7M ($0.45/share) vs $6.0M ($0.40) year ago.
Cash $18.6M at June 30, 2026; expected to fund operations into H2 2027.
Private placement up to ~$49M gross (~$15M upfront) to advance pulmonary hypertension program.
FDA aligned on Phase 2b design for Auxora in acute pancreatitis; primary endpoint new-onset severe respiratory failure.
Auxora Phase 1b PAH data and CM5480 IND submission both anticipated mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.